LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 3001 | 5013 | 0.5987 | 0.4564 |
MDA-MB-231 | PLX-4720 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 5164 | 5013 | 1.0301 | 1.0408 |
MDA-MB-231 | QL-X-138 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4191 | 5013 | 0.8360 | 0.7779 |
MDA-MB-231 | QL-XII-47 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 2885 | 5013 | 0.5755 | 0.4251 |
MDA-MB-231 | Radicicol | 0.37 | uM | LJP5 | 72 | hr | 1311 | 2498 | 5013 | 0.4983 | 0.3206 |
MDA-MB-231 | Radicicol | 0.37 | uM | LJP6 | 72 | hr | 1311 | 2483 | 5013 | 0.4953 | 0.3165 |
MDA-MB-231 | Seliciclib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4845 | 5013 | 0.9665 | 0.9546 |
MDA-MB-231 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 5229 | 5013 | 1.0431 | 1.0584 |
MDA-MB-231 | XL147 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4849 | 5013 | 0.9673 | 0.9557 |
MDA-MB-231 | Saracatinib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 2910 | 5013 | 0.5804 | 0.4318 |
MDA-MB-231 | Selumetinib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 2820 | 5013 | 0.5626 | 0.4076 |
MDA-MB-231 | Sirolimus | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4250 | 5013 | 0.8477 | 0.7937 |
MDA-MB-231 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4824 | 5013 | 0.9623 | 0.9489 |
MDA-MB-231 | SU11274 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 5082 | 5013 | 1.0137 | 1.0186 |
MDA-MB-231 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4886 | 5013 | 0.9746 | 0.9656 |
MDA-MB-231 | TGX221 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4516 | 5013 | 0.9008 | 0.8656 |
MDA-MB-231 | Torin1 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 1984 | 5013 | 0.3959 | 0.1818 |
MDA-MB-231 | Torin2 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 1576 | 5013 | 0.3145 | 0.0716 |
MDA-MB-231 | Tozasertib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 1469 | 5013 | 0.2930 | 0.0425 |
MDA-MB-231 | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 1682 | 5013 | 0.3356 | 0.1002 |
MDA-MB-231 | TWS119 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4706 | 5013 | 0.9388 | 0.9171 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4824 | 5013 | 0.9622 | 0.9488 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4318 | 5013 | 0.8614 | 0.8123 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP6 | 72 | hr | 1311 | 3880 | 5013 | 0.7739 | 0.6938 |
MDA-MB-231 | WYE-125132 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 2150 | 5013 | 0.4289 | 0.2265 |